<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777879</url>
  </required_header>
  <id_info>
    <org_study_id>14-01546</org_study_id>
    <nct_id>NCT02777879</nct_id>
  </id_info>
  <brief_title>Lung Microbiome and Inflammation in Early COPD</brief_title>
  <official_title>Lung Microbiome and Inflammation in Early Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cross sectional case controlled study to assess lung microbiome and inflammation in
      smokers with and without Chronic Obstructive Pulmonary Disease (COPD). Investigators will
      look at active bacterial metabolic pathways in the lower airways using metagenomic and
      metabolomic approaches an assess relationships among microbiome, metagenome, metabolome and
      host immune responses in COPD and controls. Investigators believe COPD cases will have higher
      prevalence of pneumotype supraglottic predominant taxa (SPT) than matched controls.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Site specific microbiome (supraglotic area) constituents using background subtraction and source tracking approaches via a multivariable conditional logistic regression model. following broncho-alveolar lavage, BAL</measure>
    <time_frame>4 Hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bacterial metabolic pathways in the lower airways using metagenomic and metabolomic approaches</measure>
    <time_frame>4 Hours</time_frame>
    <description>Bioinformatic methods such as Procrustes will be used to integrate the analysis of the generated multi-omic datasets through this study to attain a more accurately defined COPD phenotype. By elucidating the interplay between bacterial composition, microbiome functional repertoire, metabolism, and immunological status in the human lung, we will obtain further insights for hypothesis generation into the pathophysiological mechanisms underlying COPD.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Chronic Obstuctive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Chronic Obstructive Pulmonary Disease (COPD)</arm_group_label>
    <description>Case of early COPD (GOLD 1-2, FEV1/FVC&lt;70 and FEV1&gt;50%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>No obstruction (FEV1/FVC&lt;70). Controls will be recruited after each case and will be matched by: age (±5 year), 2) gender, 3) smoking (±5 pack-year) and 4) BMI (±5).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchoscopy</intervention_name>
    <description>Flexible bronchoscopy with bronchoalveolar lavage (BAL) and bronchial brushings will be done in a standardized manner. The bronchoscope tip is sequentially wedged in sub-segments where BAL will be performed on a total of two segments of the lung (120 ml in each segment for a total of 360 ml). Two brushes will be done under direct visualization in both segments. Selection of segments to sample will be based on where abnormalities are in imaging.</description>
    <arm_group_label>Chronic Obstructive Pulmonary Disease (COPD)</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Microbial DNA will be extracted from sputum and BAL fluid. Variable 16S rRNA gene regions
      will be amplified by PCR using bar-coded primers flanking a portion of marker gene. PCR
      products will be sequenced in the NYU Genome Technology Center using MiSeq platform
      (Illumina).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Utilizing cohorts built at NYU over the last several years, this project is uniquely
        positioned to investigate the microbiome signatures among subjects with COPD.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Case definition: Smokers (&gt;20 pack-year) with airflow obstruction (FEV1/FVC&lt;70) and
             FEV1&gt;50% predicted (early COPD GOLD 1 or 2)

          -  Control definition: Smokers with normal spirometry will serve as controls.

        Exclusion Criteria:

          -  FEV1 &lt; 70%.

          -  Significant cardiovascular disease defined as abnormal EKG, known or suspected
             coronary artery disease or congestive heart failure.

          -  Diabetes mellitus

          -  Significant liver or renal disease

          -  Severe coagulopathy (INR &gt; 1.4, PTT &gt; 40 seconds and platelet count &lt; 150x103 cells).

          -  Pregnancy

          -  ETOH use of more than &gt;6 beers or &gt;4 mixed drinks daily

          -  Lack of capacity to provide informed consent.

          -  Antibiotic or inhaled steroid use within the prior six months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leopoldo Segal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathryn Norris</last_name>
    <email>Kathryn.Norris@nyumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adrienne Scott</last_name>
    <email>scotta06@nyumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Norris</last_name>
      <email>Kathryn.Norris@nyumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Adrienne Scott</last_name>
      <email>Adrienne.Scott@nyumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Doreen J Addrizzo-Harris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rany Condos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Lau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashwin Basavaraj, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael D Weiden, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yonghua Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

